Effects of saxagliptin: A Synthesis of Findings from 19 Studies

  1. Home
  2. Effects of saxagliptin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of saxagliptin: A Synthesis of Findings from 19 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of saxagliptin: A Synthesis of Findings from 19 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has shown efficacy in improving glycemic control in patients with type 2 diabetes. 8 . It works by increasing insulin secretion after meals and lowering blood sugar. 3 .

Saxagliptin has also been shown to have a protective effect against gentamicin-induced kidney damage in rats. 10 This suggests that saxagliptin may have a protective effect on the kidneys in humans as well.

However, a recent large cardiovascular outcome trial in patients with type 2 diabetes (T2DM) demonstrated excess heart failure hospitalization with saxagliptin. 5 This finding raises concerns about the potential risk of heart failure with saxagliptin use.

Further studies have shown that saxagliptin, when added to metformin, can improve glycemic control and potentially reduce cardiovascular disease risk in patients with type 2 diabetes. 11 These studies suggest that saxagliptin may have a synergistic effect with metformin.

Saxagliptin is generally well-tolerated, but it is important to be aware of its potential side effects. 19 Some reported side effects include increased risk of infections such as nasopharyngitis.

Benefits and Risks

Benefit Summary

Saxagliptin can improve glycemic control in patients with type 2 diabetes. It may also have protective effects on the kidneys and potentially reduce cardiovascular disease risk. Saxagliptin is generally well-tolerated.

Risk Summary

Saxagliptin may increase the risk of heart failure. It may also increase the risk of infections, such as nasopharyngitis.

Comparison of Studies

Similarities

Many studies have shown that saxagliptin can improve glycemic control in patients with type 2 diabetes.

Differences

The effects of saxagliptin may vary depending on the specific patient population and the combination of treatments used. For instance, while saxagliptin has been shown to reduce acute glucose fluctuations in patients taking metformin and sulfonylurea, it may have different effects in patients using other combinations of medications.

Consistency and Contradictions of Results

While numerous studies demonstrate that saxagliptin can enhance glycemic control in patients with type 2 diabetes, some studies suggest a potential increase in the risk of heart failure. Further research is necessary to fully comprehend this potential risk.

Practical Implications and Considerations

Saxagliptin can be a valuable tool for improving glycemic control in patients with type 2 diabetes. However, the potential risk of heart failure must be considered. It is crucial for patients to discuss their individual circumstances and health conditions with their healthcare providers to determine the most appropriate treatment approach.

Limitations of Current Research

The current research on saxagliptin and heart failure is limited. More research is needed to fully understand the risks associated with saxagliptin use and to determine whether there are specific patient populations who may be more susceptible to heart failure.

Future Research Directions

Future research should focus on further investigating the potential risk of heart failure with saxagliptin use. Additional research should also be conducted to better understand the effects of saxagliptin on other organs and systems, such as the kidneys and cardiovascular system.

Conclusion

Saxagliptin shows potential as a treatment for type 2 diabetes, offering benefits such as improved glycemic control and possible protective effects on the kidneys. However, its potential association with increased heart failure risk calls for careful consideration. Patients should engage in open conversations with their doctors to determine the most suitable treatment plan, taking into account individual risk factors and potential benefits.

Literature analysis of 19 papers
Positive Content
18
Neutral Content
1
Negative Content
0
Article Type
9
1
0
2
19
1.

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Author: CobbleMichael E, FrederichRobert

Glycemic control
Cardiovascular disease

Saxagliptin, a dipeptidyl peptidase-4 inhibitor, effectively improved glycemic control in patients with type 2 diabetes mellitus (T2DM) while having neutral effects on cardiovascular risk factors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.

Author: LiuQian, Ou-YangQiu-Geng, LinQian-Meng, LuXiang-Ran, MaYa-Qing, LiYing-Hui, XuRen-Ai, LinDong-Dong, HuGuo-Xin, CaiJian-Ping

Diabetes treatment
Drug toxicity
Treatment failure

This study evaluated the catalytic activities of 27 CYP3A4 variants on saxagliptin metabolism in vitro. Most variants showed decreased metabolic activity compared to wild-type CYP3A4.1, suggesting that genetic polymorphisms in CYP3A4 may influence saxagliptin metabolism and potentially affect drug efficacy and safety.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance.

Author: RezkiAmel, FysekidisMarinos, ChihebSabrina, VicautEric, CossonEmmanuel, ValensiPaul

Type 2 diabetes prevention

This pilot study investigated the acute and chronic effects of saxagliptin on glucose levels in obese patients with impaired glucose tolerance.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF).

Author: SandhuPaul, OngJann P, GargVinay, AltahaMustafa, BelloOlubenga, SingalSewa R, VermaSubodh, YanAndrew T, ConnellyKim A

T2DM treatment
Heart failure

This study investigated the impact of saxagliptin on cardiac structure and function using CMR in patients with T2DM without pre-existing heart failure. The findings will help understand the potential cardiac effects of saxagliptin in patients with T2DM.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.

Author: FangHui, XuFengmei, DuJin, LiangLi, LiWei, ShenLiya, WangXueying, XuChun, BianFang, MuYiming

Improved glycemic control

Both saxagliptin and acarbose, when added to metformin, reduced HbA1c regardless of baseline HbA1c, age, body mass index and renal function. However, only saxagliptin was effective at a stable glycemic control (FPG and PPG).

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study.

Author: KoskaJ, OsredkarT, D'SouzaK, SandsM, SinhaS, ZhangW, MeyerC, ReavenP D

Lower TxNIP expression
Lower postprandial glucose
Reduced IL-8 secretion

Saxagliptin, a dipeptidyl peptidase-4 inhibitor, showed a modest effect on adipose tissue inflammation in overweight or obese individuals without diabetes. The study found that saxagliptin therapy did not improve adipose tissue arteriole vasodilation or postprandial endothelial function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.

Author: DoreFiona J, DominguesCleyton C, AhmadiNeeki, KunduNabanita, KropotovaYana, HoustonSara, RouphaelCarol, MammadovaAytan, WitkinLinda, KhiyamiAnamil, AmdurRichard L, SenSabyasachi

Improved glycemic control
Reduced cardiovascular risk

This study investigated the potential cardiovascular benefits of adding saxagliptin, a DPP-IV inhibitor, to metformin in patients with type 2 diabetes. The research aimed to assess whether this combination could reduce cardiovascular disease risk and improve glycemic control.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.

Author: WangZixuan, XuDengcheng, HuangLanhui, ZhangTiantian, WangJunqiao, ChenQing, KongLei, ZhouXinli

Blood glucose control
β-cell function improvement
Obesity

This study assessed the effect of saxagliptin monotherapy on blood glucose and islet β-cell function in obese patients with newly diagnosed pre-diabetes and abnormal fat metabolism. Saxagliptin monotherapy may prevent or delay the progression of IGT or IFG to type 2 diabetes mellitus in obese patients with newly diagnosed pre-diabetes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Author: PerlShira, CookWilliam, WeiCheryl, OhmanPeter, HirshbergBoaz

Hypoglycemia risk

This study evaluated baseline β-cell function as a potential risk factor for the development of hypoglycemia when saxagliptin or glimepiride was added in patients aged ≥65 years whose type 2 diabetes was poorly controlled on stable metformin monotherapy.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

15.

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.

Author: LiFeng-Fei, JiangLan-Lan, YanReng-Na, ZhuHong-Hong, ZhouPei-Hua, ZhangDan-Feng, SuXiao-Fei, WuJin-Dan, YeLei, MaJian-Hua

Improved glycemic control
Lower insulin dose
None reported

This single-center, randomized, control, open-labeled trial investigated whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improves blood glycemic control in patients with newly diagnosed type 2 diabetes (T2D). After 4-week therapy, patients with saxagliptin add-on therapy exhibited further improvement of mean amplitude glycemic excursion (MAGE) compared with the control group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

17.

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.

Author: RoyD, ChadwickK D, TatarkiewiczK, LaCerteC, BergholmA-M, BrodieT, MangipudyR S, ParkesD, GrazianoM J, ReillyT P

Pancreatic pathology

Glucagon-like peptide-1 (GLP-1)-based therapies have been suggested to potentially increase the risk of pancreatic pathology. Extensive non-clinical and clinical safety testing of exenatide and saxagliptin provides complementary data regarding the potential for drug-induced pancreatic safety signals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.

Author: OttChristian, RaffUlrike, SchmidtStephanie, KistnerIris, FriedrichStefanie, BramlagePeter, HaraznyJoanna M, SchmiederRoland E

Retinal microvascular effects

This study investigated the effects of the DPP-4-inhibitor saxagliptin on early retinal microvascular changes in patients with diabetes mellitus.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Saxagliptin overview: special focus on safety and adverse effects.

Author: AliShamsa, FonsecaVivian

Blood glucose lowering
T2DM treatment
Weight neutrality
CYP3A4/A5 inhibition
Infections
Saxagliptin use

Saxagliptin is a medication used to treat type 2 diabetes. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This study reviewed the clinical efficacy, safety, and tolerability of saxagliptin, concluding that it is effective, generally safe, and well tolerated, with a small increase in the incidence of infections.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.